4DMedical (Imbio)

by 4DMedical  · Based in Australia → — Actionable insights into cardiothoracic health.
Cardiology Pulmonology Radiology

Regulatory Status Disclosed

Overview

4DMedical is a global medical technology company that provides advanced imaging software for respiratory diagnostics. Through its patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity. In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. This acquisition expanded 4DMedical’s portfolio to include AI-driven diagnostic tools that provide comprehensive cardiothoracic analysis from standard CT scans.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Quantitative lung ventilation analysis (XV LVASu00ae, CT LVASu2122)
  • Non-contrast ventilation-perfusion mapping (CT:VQu2122)
  • Coronary Artery Calcification (CACu2122) quantification
  • Early IPF Detection (IQ-UIPu2122)
  • Functional Lung Density Analysis (LDAfu2122)
  • Lung Density Analysis – Inspiration (LDAiu2122) for emphysema assessment
  • Lung Texture Analysis (LTAu2122) for interstitial lung disease assessment
  • Pulmonary Hypertension Assessment (PHAu2122)
  • Automated airway measurement
  • Cloud-based Software-as-a-Service (SaaS) delivery model

Use Cases

  • Early detection and diagnosis of respiratory deficiencies
  • Monitoring changes in lung function over time
  • Assessment of emphysema and COPD
  • Support for lung cancer screening programs
  • Pulmonary embolism workups and CTEPH assessment
  • Surgical planning and pulmonary vascular disease assessment

What Physicians Need to Know

Cardiac CT/MRI Analysis
4DMedical (Imbio) offers AI-powered solutions for analyzing cardiac CT scans. Their Coronary Artery Calcification (CAC) software uses AI to identify and quantify coronary artery calcification from non-contrast chest CT imaging, including both new and existing gated or ungated, standard or low-dose scans. This tool provides objective, reproducible quantification, 3D visualization, and artery-specific scoring for comprehensive and efficient interpretation. Additionally, Imbio's RV/LV Analysisu2122 algorithm, which is FDA 510(k) cleared, provides a rapid, automated assessment of potential right ventricular dilation by measuring the ratio of the maximum diameter of the right versus the left ventricle from contrast-enhanced chest CT scans (CTPA's). This ratio is a key patient risk indicator for various pulmonary conditions like pulmonary embolism.
Coronary Artery Assessment
The CACu2122 software by 4DMedical (Imbio) is specifically designed for coronary artery assessment. It provides actionable cardiovascular risk data by detecting, visualizing, and quantifying coronary artery calcification from non-contrast chest CT scans. The software generates an Agatston Score (AS), which is the gold standard for coronary calcium burden, Arterial Age, and detailed lesion count, volume, and mass broken down by individual arteries (LM, LAD, LCX, RCA). It also offers 3D visualizations for rapid interpretation. This analysis can be performed on routine chest CT scans, such as those done for lung cancer screening, without the need for additional imaging.
Heart Failure Risk Prediction
While 4DMedical (Imbio)'s CACu2122 tool provides actionable cardiovascular risk data that can contribute to overall heart health assessment, and the RV/LV Analysisu2122 identifies right ventricular dilation which is a risk indicator for certain pulmonary and cardiopulmonary diseases, the provided information does not explicitly detail a dedicated 'Heart Failure Risk Prediction' feature using machine learning models or specific algorithms for predicting heart failure as a primary outcome.
AHA/ACC Guideline Alignment
The provided information does not explicitly state alignment with AHA/ACC guidelines. However, the Agatston Score (AS) provided by the CACu2122 software is considered the gold standard for coronary calcium burden, which is a widely recognized metric in cardiovascular risk assessment.
Physician Tip

For radiologists and cardiologists, 4DMedical (Imbio)'s CACu2122 tool can be invaluable for efficiently assessing coronary artery calcification from existing non-contrast chest CT scans, streamlining the evaluation of patients with dyspnea and aiding in distinguishing between cardiac and pulmonary causes. The automated RV/LV Analysisu2122 provides crucial quantitative data on right ventricular dilation, which can assist in risk stratification for pulmonary conditions like pulmonary embolism, potentially saving reporting time and standardizing reporting of right heart strain. These tools can provide objective, reproducible quantification and visualization, enhancing diagnostic accuracy and guiding referrals.

4DMedical (Imbio) solutions are designed for integration into clinical workflows. The CACu2122 software results are directly routed to PACS for immediate review and integration. Imbio's products, including Lung Density Analysis (LDA) and RV/LV Analysis, are available through global partners and can be integrated into radiology reporting workflows via platforms like the Nuance AI Marketplace and PowerShare Network. 4DMedical has also partnered with Blackford Analysis Inc. to distribute Imbio's medical imaging AI solutions through the Blackford Platformu2122, which is an AI marketplace that consolidates disparate AI clinical applications and provides access through integration, workflow, orchestration, and reporting. Imbio's Core Computing Platform (CCP) offers both cloud and on-premise hosted options for running computationally-intensive image algorithms, integrating with native DICOM tools and workflows.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentCloud (Imbio Cloud in AWS) or On-premise (Imbio Enterprise)
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Cardiology, Pulmonology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate 4DMedical (Imbio)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for 4DMedical (Imbio).

View all on YouTube

Frequently Asked Questions

4DMedical, through its acquisition of Imbio, offers AI tools for cardiothoracic analysis. One key tool is the RV/LV Analysisu2122 algorithm, which rapidly and automatically measures heart ventricles to provide a right-to-left ventricle ratio, serving as a risk indicator for pulmonary conditions like pulmonary embolism. Additionally, the Coronary Artery Calcification (CACu2122) tool uses AI to identify and quantify coronary artery calcification from non-contrast chest CT imaging, aiding in cardiovascular risk assessment and distinguishing between cardiac and pulmonary causes of dyspnea.
Imbio's RV/LV Analysisu2122 algorithm has received 510(k) clearance from the U.S. Food & Drug Administration (FDA). Similarly, the Coronary Artery Calcification (CAC) tool is also FDA-cleared. 4DMedical's solutions, including those from Imbio, are regulatory cleared and aim to transform patient diagnosis and treatment.
While AI in cardiac imaging offers significant advancements, general challenges include data standardization, algorithm validation across diverse patient populations, and ethical considerations regarding patient data privacy. Although 4DMedical (Imbio) tools are regulatory cleared, the broader integration of AI in cardiology still requires collaborative efforts to ensure safe and effective deployment.
The field of AI in cardiac imaging is evolving, with various innovative software solutions emerging. While specific direct alternatives to 4DMedical (Imbio)'s precise offerings aren't detailed, other AI-powered tools exist for cardiac MRI analysis, ECG interpretation, and lung nodule detection, which may indirectly impact cardiothoracic evaluations.
4DMedical's XV Lung Ventilation Analysis Software (XV LVASu00ae) and CT LVASu2122 products have received U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement. As of FY2024, XV LVASu00ae scans can be billed to CMS with a reimbursement of US$299, and CT LVASu2122 at US$650, when conducted in a U.S. hospital outpatient facility for Medicare beneficiaries. This reimbursement also serves as a guide for private health insurers.
Imbio's RV/LV Analysisu2122 algorithm provides results automatically, including a full report of quantitative findings that are added directly to the patient imaging study within minutes, potentially reducing reporting times. The CACu2122 tool also offers direct routing to PACS for immediate review and integration into clinical workflow, providing rapid, fully-automated AI analysis compatible with any non-contrast chest CT.
4DMedical's acquisition of Imbio aims to provide a broader cardiothoracic analysis from standard chest CTs, offering functional, structural, and risk-based analysis for both lung and heart disease. This comprehensive approach can aid in evaluating patients with unexplained shortness of breath, helping clinicians determine if symptoms are cardiac, pulmonary, or multifactorial.

Related Tools

Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.
ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System, ACUSON Origin ICE Diagnostic Ultrasound System
Siemens Medical Solutions, USA
Cardiology AI
Siemens Healthineers offers advanced AI-powered ultrasound systems, including the ACUSON Origin for comprehensive cardiovascular care and the ACUSON Sequoia for high-performance general imaging with BioAcoustic™ technology.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
ACUSON Sequoia Diagnostic Ultrasound System, ACUSON Sequoia Select Diagnostic Ultrasound System, ACUSON Origin Diagnostic Ultrasound System
Siemens Medical Solutions USA
Cardiology AI
Siemens Healthineers offers the ACUSON Sequoia, ACUSON Sequoia Select, and ACUSON Origin ultrasound systems, providing advanced imaging for various medical needs. The Sequoia line focuses on high-resolution imaging with deep penetration and reduced variability, while the AI-powered ACUSON Origin specializes in comprehensive cardiovascular diagnostics and interventions.
R30 Diagnostic Ultrasound System
Samsung Medison Co.
Cardiology AI
The Samsung Medison R30 Diagnostic Ultrasound System is a general-purpose, mobile, software-controlled diagnostic ultrasound system that offers a wide range of imaging capabilities and analysis tools for various clinical applications.

See all Cardiology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-08-05 | First Added: 2026-08-05
AI Tool Finder
AI-powered search. Results may not be comprehensive.